Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

The user experienced hair loss after 21 months of using oral minoxidil and finasteride and is considering switching to dutasteride. Others suggest it might be temporary and recommend staying consistent or trying additional methods like hair loss shampoo, microneedling, or checking vitamin levels.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

The conversation discusses the effectiveness and value of a Locklabs pill containing finasteride, minoxidil, biotin, and a low dose of dutasteride for hair loss. The user is uncertain if the .1mg dutasteride dosage is sufficient and worth the cost.

A 24-year-old is struggling with hair loss despite using treatments like dutasteride, oral minoxidil, RU58841, and considering a hair transplant. They are advised to continue medication, possibly increase dosages, and explore additional treatments like tretinoin and tacrolimus.

The conversation is about a user switching from finasteride to dutasteride after 4 years due to continued hair recession and miniaturization. The user plans to gradually increase to 1mg of dutasteride daily.

A 24-year-old male is increasing his dutasteride dosage from 0.5mg to 1mg daily due to continued hair thinning despite using finasteride, dutasteride, and topical minoxidil. Another user suggests trying oral minoxidil for potentially better results.

A 21-year-old started using finasteride 0.5mg every other day, along with Rogaine, Nizoral, biotin, and vitamin D3, to combat significant hair loss. Users advised that finasteride might cause initial shedding but could lead to maintenance or regrowth, and some suggested delaying Rogaine use.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

The user switched from finasteride to dutasteride after 1.5 years without results. They are hopeful the new treatment will work.

Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

A 19-year-old started using dutasteride for hair loss due to androgenic alopecia concerns. Users debated the effectiveness of oral versus topical treatments, with some recommending finasteride and minoxidil.

The user shared their successful hair regrowth experience using Dutas, oral and topical minoxidil, vitamin D3, zinc, biotin, a laser cap, natural shampoos, ketoconazole shampoo, retinoic acid lotion, and mesotherapy. They reported no side effects and significant improvement in hair thickness and color over six months.

The conversation is about the effectiveness of using less than 20mg of RU58841, specifically 12.5mg, for hair loss treatment. People are discussing their experiences with different dosages of RU58841.

A 28-year-old male shares progress on hair loss treatment using 0.5mg dutasteride and 5mg minoxidil, experiencing initial shedding but encouraged by community support. He also uses ketoconazole occasionally based on scalp oiliness.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The user achieved significant hair regrowth using only dutasteride, noticing results after 8-9 months despite initial shedding. They did not use minoxidil due to inconvenience but still experienced permanent hair growth.

RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.

The user switched from finasteride to dutasteride after 30 months with no progress, experiencing a significant shed initially. The current treatment includes daily dutasteride, oral minoxidil, topical finasteride and minoxidil, derma stamping, PRP, and calecim exosomes.

The user noticed potential hair growth after 13 days of using RU58841, alongside a regimen of oral minoxidil, finasteride, and topical minoxidil. Others think it's too soon to see results, and some are surprised by the high dosage of oral minoxidil.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

A 17-year-old shares their hair loss treatment, using oral finasteride, dutasteride, stemoxydine, alfatradiol, and a placebo product, but cannot use minoxidil due to an allergic reaction. Others discuss similar treatments and question the use of dutasteride at a young age.

A 28-year-old male reports progress in hair regrowth using 5mg Minoxidil and 0.5mg Dutasteride, noting improvement in the crown area. Another user shares similar positive results since starting treatment in January.

The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.

A user switched from Anageninc to Aesthetic Cosmetics for RU58841 and experienced increased shedding, questioning the product's authenticity. They seek advice on reliable sources for RU58841 in Australia.